Retrieve available abstracts of 25 articles: HTML format
Single Articles
June 2025
HUANG YQ, Chen XB, Cui YF, Yang F, et al Enhanced risk stratification for stage II colorectal cancer using deep
learning-based CT classifier and pathological markers to optimize adjuvant
therapy decision.
Ann Oncol. 2025 Jun 4:S0923-7534(25)00766-5. doi: 10.1016/j.annonc.2025. PubMedAbstract available
RIEDL JM, Fece de la Cruz F, Lin JJ, Parseghian C, et al Genomic landscape of clinically acquired resistance alterations in patients
treated with KRAS(G12C) inhibitors.
Ann Oncol. 2025;36:682-692. PubMedAbstract available
May 2025
WILLIAMS H, Fokas E, Diefenhardt M, Lee C, et al Survival among patients treated with total mesorectal excision or selective
watch-and-wait after total neoadjuvant therapy: a pooled analysis of the
CAO/ARO/AIO-12 and OPRA randomized phase II trials.
Ann Oncol. 2025;36:543-547. PubMedAbstract available
February 2025
BARON D, Pace Loscos T, Schiappa R, Barbet N, et al A phase III randomised trial on the addition of a contact X-ray brachytherapy
boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early
rectal adenocarcinoma: 5 year results of the OPERA trial.
Ann Oncol. 2025;36:208-215. PubMedAbstract available
January 2025
SELIGMANN JF, Morton D, Elliott F, Handley K, et al Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt
locally advanced colon cancer: results following an extended biomarker panel on
the FOxTROT Trial embedded phase II population.
Ann Oncol. 2025 Jan 11:S0923-7534(25)00002-X. doi: 10.1016/j.annonc.2024. PubMedAbstract available
December 2024
MARTINEZ-CASTEDO B, Camblor DG, Martin-Arana J, Carbonell-Asins JA, et al Minimal residual disease in colorectal cancer. Tumor-informed versus
tumor-agnostic approaches: unraveling the optimal strategy.
Ann Oncol. 2024 Dec 13:S0923-7534(24)04981-0. doi: 10.1016/j.annonc.2024. PubMedAbstract available
CANDIA L, Cervantes A, Martinelli E Updated treatment recommendations for third and further lines of treatment in
advanced colorectal cancer: from the ESMO Metastatic Colorectal Cancer Living
Guideline.
Ann Oncol. 2024 Dec 3:S0923-7534(24)04952-4. doi: 10.1016/j.annonc.2024. PubMed
ANDRE T, Shiu KK, Kim TW, Jensen BV, et al Pembrolizumab Versus chemotherapy in microsatellite instability-high or mismatch
repair-deficient metastatic colorectal cancer: 5-year follow-up from the
randomized phase 3 KEYNOTE-177 study.
Ann Oncol. 2024 Dec 2:S0923-7534(24)04949-4. doi: 10.1016/j.annonc.2024. PubMedAbstract available
BEEHUAT TAN I, Lui R, Yan K, Lam R, et al Investigating the 'liquid-solid interface' in the comprehensive genomic profiling
of metastatic colorectal cancer for guiding treatment-where do we draw the line?
Ann Oncol. 2024;35:1067-1070. PubMed
November 2024
DE WILT JHW, van der Kruijssen DEW, Koopman M Reply to Letter to the Editor "Optimising Treatment Strategies in Metastatic
Colorectal Cancer: Insights from CAIRO4" by Guzel et al.
Ann Oncol. 2024 Nov 4:S0923-7534(24)04052-3. doi: 10.1016/j.annonc.2024. PubMed
KATAOKA K, Mori K, Nakamura Y, Watanabe J, et al Survival benefit of adjuvant chemotherapy based on molecular residual disease
detection in resected colorectal liver metastases: subgroup analysis from
CIRCULATE-Japan GALAXY.
Ann Oncol. 2024;35:1015-1025. PubMedAbstract available
BERCZ A, Park BK, Pappou E, Nemirovsky D, et al Organ preservation after neoadjuvant long-course chemoradiotherapy versus
short-course radiotherapy.
Ann Oncol. 2024;35:1003-1014. PubMedAbstract available
October 2024
GUZEL HG, Ilhan Y, Onder AH Optimising Treatment Strategies in Metastatic Colorectal Cancer: Insights from
CAIRO4.
Ann Oncol. 2024 Oct 10:S0923-7534(24)04053-5. doi: 10.1016/j.annonc.2024. PubMed
ROMESSER PB, Cercek A Optimizing Rectal Cancer Treatment: A Path Towards Personalization.
Ann Oncol. 2024;35:831-835. PubMed
CONROY T, Castan F, Etienne PL, Rio E, et al Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy
in patients with locally advanced rectal cancer: long-term results of the
UNICANCER-PRODIGE 23 trial.
Ann Oncol. 2024;35:873-881. PubMedAbstract available
LIN ZY, Zhang P, Chi P, Xiao Y, et al Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy
in locally advanced rectal cancer (UNION): early outcomes of a multicenter
randomized phase III trial.
Ann Oncol. 2024;35:882-891. PubMedAbstract available
August 2024
CIARDIELLO D, Bielo LB, Napolitano S, Martinelli E, et al Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and
identifies cancer vulnerabilities in patients with RAS/BRAF(V600E) wild type
metastatic colorectal cancer in the CAPRI 2-GOIM trial.
Ann Oncol. 2024 Aug 28:S0923-7534(24)03914-0. doi: 10.1016/j.annonc.2024.08.2334 PubMedAbstract available
ROS J, Matito J, Villacampa G, Comas R, et al Corrigendum to "Plasmatic BRAF-V600E allele fraction as a prognostic factor in
metastatic colorectal cancer treated with BRAF combinatorial treatments": [Annals
of Oncology 34 (2023) 543-552].
Ann Oncol. 2024 Aug 12:S0923-7534(23)00796-2. doi: 10.1016/j.annonc.2023. PubMed
July 2024
BIONDO S, Frago R, Kreisler E Primary tumor resection for asymptomatic colorectal cancer with unresectable
metastasis: the end of the dilemma.
Ann Oncol. 2024 Jul 3:S0923-7534(24)00767-1. doi: 10.1016/j.annonc.2024. PubMed
CECCHINI M, Sundar R Proofreading the way: immune checkpoint inhibitors in polymerase epsilon/polymerase delta
(POLE/POLD1)-altered colorectal cancer.
Ann Oncol. 2024;35:582-584. PubMed
June 2024
VAN DER KRUIJSSEN DEW, Elias SG, van de Ven PM, van Rooijen KL, et al Upfront resection versus no resection of the primary tumor in patients with
synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study
conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer
Group.
Ann Oncol. 2024 Jun 7:S0923-7534(24)00722-1. doi: 10.1016/j.annonc.2024. PubMedAbstract available
May 2024
AMBROSINI M, Rousseau B, Manca P, Artz O, et al Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic
colorectal cancer.
Ann Oncol. 2024 May 3:S0923-7534(24)00104-2. doi: 10.1016/j.annonc.2024. PubMedAbstract available
BRENNER H, Niedermaier T, Hoffmeister M Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced
colorectal neoplasms.
Ann Oncol. 2024;35:476-477. PubMed
April 2024
KELSEN D, Ben-Aharon I, Gordon N Identifying Genetic Loci Associated with an Increased Risk for Early Onset
Colorectal Cancer.
Ann Oncol. 2024 Apr 3:S0923-7534(24)00106-6. doi: 10.1016/j.annonc.2024. PubMed
February 2024
LASKAR RS, Qu C, Huyghe JR, Harrison T, et al Genome-wide association study and Mendelian randomization analyses provide
insights into the causes of early-onset colorectal cancer.
Ann Oncol. 2024 Feb 24:S0923-7534(24)00058-9. doi: 10.1016/j.annonc.2024. PubMedAbstract available